{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:29:30Z","timestamp":1760984970904},"reference-count":31,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.vaccine.2014.02.017","type":"journal-article","created":{"date-parts":[[2014,3,20]],"date-time":"2014-03-20T03:00:57Z","timestamp":1395284457000},"page":"2851-2858","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cancer vaccine characterization: From bench to clinic"],"prefix":"10.1016","volume":"32","author":[{"given":"K.","family":"de la Luz-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Rabasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.F.","family":"Santo-Tom\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.02.017_bib0005","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/hyb.1998.17.527","article-title":"Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody","volume":"17","author":"V\u00e1zquez","year":"1998","journal-title":"Hybridoma"},{"key":"10.1016\/j.vaccine.2014.02.017_bib0010","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1089\/hyb.1995.14.551","article-title":"Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids","volume":"14","author":"V\u00e1zquez","year":"1995","journal-title":"Hybridoma"},{"key":"10.1016\/j.vaccine.2014.02.017_bib0015","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/glycob\/8.7.695","article-title":"Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid-containing gangliosides","volume":"8","author":"Moreno","year":"1998","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2014.02.017_bib0020","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.4049\/jimmunol.168.5.2523","article-title":"An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients","volume":"168","author":"Alfonso","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.017_bib0025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4161\/cbt.6.2.3574","article-title":"Active immunotherapy with Racotumomab anti-Idiotype vaccine in patients with small cell lung cancer. Report of a phase I trial","volume":"6","author":"Neninger","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.vaccine.2014.02.017_bib0030","first-page":"5165","article-title":"Gangliosides expressed in human breast cancer","volume":"56","author":"Marquina","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2014.02.017_bib0035","first-page":"751","article-title":"Antitumor properties of an anti-idiotypic monoclonal antibody in relation to Nglycolylcontaining gangliosides","volume":"7","author":"Vazquez","year":"2000","journal-title":"Oncol Rep"},{"key":"10.1016\/j.vaccine.2014.02.017_bib0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1521-6616(03)00036-6","article-title":"Immune responses in breast cancer patients immunized with an antiidiotype antibody mimicking NeuGc-containing gangliosides","volume":"107","author":"Diaz","year":"2003","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2014.02.017_bib0045","doi-asserted-by":"crossref","DOI":"10.4161\/cbt.6.12.5000","article-title":"Racotumomab anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb\/IV patients","author":"Alfonso","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.vaccine.2014.02.017_bib0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1472-6750-11-112","article-title":"Physicochemical and biological characterization of 1E10 anti-idiotype vaccine","volume":"11","author":"Machado","year":"2011","journal-title":"BMC Biotech"},{"issue":"5","key":"10.1016\/j.vaccine.2014.02.017_bib0055","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4161\/mabs.1.5.9630","volume":"1","author":"Reichert","year":"2009","journal-title":"Mabs"},{"issue":"2","key":"10.1016\/j.vaccine.2014.02.017_bib0060","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1006\/abio.1996.0351","article-title":"A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles","volume":"240","author":"Guile","year":"1996","journal-title":"Anal Biochem"},{"issue":"4","key":"10.1016\/j.vaccine.2014.02.017_bib0065","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/(SICI)1096-9098(199608)62:4<288::AID-JSO14>3.0.CO;2-1","article-title":"Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma","volume":"62","author":"Alonso","year":"1996","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.vaccine.2014.02.017_bib0070","article-title":"Systematic characterization of high mass accuracy influence on false discovery and probability scoring in peptide mass fingerprinting","author":"Dodds","year":"2007","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2014.02.017_bib0075","first-page":"148","article-title":"Preparation and characterization of monoclonal antibody against human carboxylesterases-II","volume":"2","author":"Wu","year":"2007","journal-title":"Chin J Cell Mol Immunol"},{"key":"10.1016\/j.vaccine.2014.02.017_bib0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1023\/A:1025771421906","article-title":"Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation","volume":"20","author":"Chi","year":"2003","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2014.02.017_bib0085","unstructured":"\u3008http:\/\/en.wikipedia.org\/wiki\/zeta_potential\u3009"},{"issue":"Pt 1","key":"10.1016\/j.vaccine.2014.02.017_bib0090","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1042\/BA20040032","article-title":"Influence of culture conditions on the N-glycosylation of a monoclonal antibody specific for recombinant hepatitis B surface antigen","volume":"41","author":"Cabrera","year":"2005","journal-title":"Biotechnol Appl Biochem"},{"key":"10.1016\/j.vaccine.2014.02.017_bib0095","unstructured":"Glycosylation patterns during fermentation. Practical high-throughput monitoring during process development and manufacturing. Genet Eng Biotechnol News. 2006;26:8."},{"issue":"2","key":"10.1016\/j.vaccine.2014.02.017_bib0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jchromb.2004.06.052","article-title":"Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells","volume":"819","author":"Beck","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"6","key":"10.1016\/j.vaccine.2014.02.017_bib0105","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jasms.2006.02.023","article-title":"Improving mass accuracy of high performance liquid chromatography\/electrospray ionization time-of-flight mass spectrometry of intact antibodies","volume":"17","author":"Gadgil","year":"2006","journal-title":"J Am Soc Mass Spectrom"},{"issue":"5","key":"10.1016\/j.vaccine.2014.02.017_bib0110","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1021\/ac00077a003","article-title":"Characterization of humanized anti-TAC, an antibody directed against the interleukin 2 receptor, using electrospray ionization mass spectrometry by direct infusion, LC\/MS, and MS\/MS","volume":"66","author":"Lewis","year":"1994","journal-title":"Anal Chem"},{"issue":"1","key":"10.1016\/j.vaccine.2014.02.017_bib0115","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ab.2005.04.012","article-title":"The removal of pyroglutamic acid from monoclonal antibodies without denaturation of the protein chains","volume":"342","author":"Werner","year":"2005","journal-title":"Anal Biochem"},{"issue":"42","key":"10.1016\/j.vaccine.2014.02.017_bib0120","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1016\/j.chroma.2010.08.044","article-title":"Separation of post-translational modifications in monoclonal antibodies by exploiting subtle conformational changes under mildly acidic conditions","volume":"1217","author":"Wang","year":"2005","journal-title":"J Chromatogr A"},{"issue":"18","key":"10.1016\/j.vaccine.2014.02.017_bib0125","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1021\/bi702238b","article-title":"Remmele RL Jr: Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation","volume":"47","author":"Liu","year":"2008","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.vaccine.2014.02.017_bib0130","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.molimm.2007.07.012","article-title":"Structural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody","volume":"45","author":"Liu","year":"2008","journal-title":"Mol Immunol"},{"issue":"42","key":"10.1016\/j.vaccine.2014.02.017_bib0135","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1016\/j.chroma.2010.08.044","article-title":"Separation of post-translational modifications in monoclonal antibodies by exploiting subtle conformational changes under mildly acidic conditions","volume":"1217","author":"Wang","year":"2010","journal-title":"J Chromatogr A"},{"issue":"11","key":"10.1016\/j.vaccine.2014.02.017_bib0140","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1023\/A:1015929109894","article-title":"Stability of protein pharmaceuticals","volume":"6","author":"Manning","year":"1989","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.vaccine.2014.02.017_bib0145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0021-9673(94)01255-D","article-title":"Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture","volume":"705","author":"Harris","year":"1995","journal-title":"J Chromatogr A"},{"issue":"2","key":"10.1016\/j.vaccine.2014.02.017_bib0150","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1006\/abio.1995.1468","article-title":"Nonselective and efficient fluorescent labeling of glycans using 2-amino benzamide and anthranilic acid","volume":"230","author":"Bigge","year":"1995","journal-title":"Anal Biochem"},{"issue":"1","key":"10.1016\/j.vaccine.2014.02.017_bib0155","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1006\/abio.1994.1478","article-title":"Analytical and preparative separation of anionic oligosaccharides by weak anion-exchange high-performance liquid chromatography on an inert polymer column","volume":"222","author":"Guile","year":"1994","journal-title":"Anal Biochem"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1400190X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1400190X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T04:32:18Z","timestamp":1716611538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1400190X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":31,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0264410X1400190X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer vaccine characterization: From bench to clinic","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}